Beijing, China

Baocai Xing

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Baocai Xing: Innovator in Cancer Research

Introduction

Baocai Xing is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the identification and treatment of tumor-initiating cells. His innovative work has led to the development of a valuable patent that addresses critical challenges in oncology.

Latest Patents

Baocai Xing holds a patent titled "Antibody and binding fragment recognizing CACNA2D1 and use thereof." This patent discloses a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method involves immunizing an animal using HEP-12 cells originating from a recurrent tumor that is rich in originating cells. Additionally, the patent describes a monoclonal antibody that specifically recognizes CACNA2D1 or antigen-binding fragments thereof. This innovation has potential applications for treating or preventing tumors or diseases related to CACNA2D1. Baocai Xing has 1 patent to his name.

Career Highlights

Baocai Xing is affiliated with the Beijing Institute for Cancer Research, where he conducts his research and development activities. His work is instrumental in advancing the understanding of cancer biology and improving therapeutic strategies.

Collaborations

Baocai Xing collaborates with notable colleagues, including Zhiqian Zhang and Wei Zhao. Their combined expertise enhances the research efforts at the Beijing Institute for Cancer Research.

Conclusion

Baocai Xing's contributions to cancer research through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly impact the treatment of cancer and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…